BRISBANE, Calif., Feb. 7 /PRNewswire-FirstCall/ -- VaxGen, Inc. announced today that it has filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K and three associated Quarterly Reports on Forms 10-Q for the year ended December 31, 2004. The reports can be found today at the link titled SEC Filings in the Investor Relations section of VaxGen’s web site at www.vaxgen.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
Next Steps
VaxGen intends to complete the following steps in order to get current with its financial reporting obligations and to re-list its common stock.
-- Submit to its independent auditors, in sequence, its Annual Reports on Form 10-K and associated Quarterly Reports on Form 10-Q for the years 2005 and 2006 and any outstanding Quarterly Reports for 2007. -- File these reports with the SEC after VaxGen’s independent auditors have completed their audits of the Annual Reports. -- Apply for listing of VaxGen’s common stock on a recognized stock exchange. -- As announced in March 2006, VaxGen no longer provides guidance on the timing related to filing its outstanding financial statements. About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases. For more information, please visit the company’s web site at www.vaxgen.com.
NOTE: This press release contains “forward-looking statements” within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the anticipated filing of the company’s outstanding quarterly and annual reports and its application for listing of its common stock. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Item 8.01 of the company’s Current Report on Form 8-K filed by VaxGen on February 16, 2006 under the heading “Risk Factors” for a more detailed description of such risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comVaxGen, Inc.
CONTACT: Lance Ignon, Vice President, Corporate Affairs of VaxGen, Inc.,+1-650-624-1016
Web site: http://www.vaxgen.com//
